What Melanotan-2 is
Melanotan-2 (MT-2, CAS 121062-08-6) is a synthetic cyclic heptapeptide and an analog of the natural hormone α-MSH. The molecule is built around a lactam bridge that stabilizes its structure and originates from melanocortin-system research at the University of Arizona in the 1980s. Unlike more selective compounds, MT-2 is regarded as a non-selective melanocortin-receptor agonist: in laboratory studies it activates MC1R, MC3R, MC4R and MC5R. This broad receptor profile is exactly why researchers used it as a tool to probe the roles of individual melanocortin receptors. This section describes only the chemical and pharmacological identity of the compound, not any use in humans. All statements refer to the published research literature and are not a recommendation.
Mechanism: melanogenesis via the MC1R receptor
The best-studied mechanism of MT-2 is its effect on melanogenesis via the MC1R receptor on melanocytes. In cell (in vitro) models, agonist binding to MC1R raises intracellular cAMP, activating protein kinase A, the transcription factor CREB and then MITF, the master regulator of pigment synthesis. This pathway preferentially drives eumelanin (brown-black pigment) production. A recent study (Tian et al., 2024) showed that upon stimulation MC1R translocates into the primary cilium via the BBSome complex, where it triggers sustained cAMP signaling that drives pigmentation genes through Sox9 and MITF. Importantly, these data come from cellular and molecular models and from animal systems, not from controlled human studies. They describe a mechanism, not an effect in humans.
Relationship to PT-141 (bremelanotide)
MT-2 is often mentioned alongside PT-141 (bremelanotide) because the two are chemically related. In the literature, PT-141 is described as a deaminated derivative and likely metabolite of MT-2: the main difference is replacement of the terminal amide group with a carboxyl group, which alters receptor selectivity. Whereas MT-2 is non-selective, PT-141's activity in research is directed more toward the central MC3R and MC4R receptors and less toward MC1R. We state this relationship purely as a mechanistic and developmental-history fact from the research literature. We attribute no human benefits to either MT-2 or PT-141; both are treated in this overview only as compounds under study and not as products for human use.
What the limited human data show
Human data on MT-2 are sparse and largely uncontrolled. The earliest assessments come from small pilot studies of melanocortin peptides in the 1990s, while much of the later reporting is based on observations of unregulated use rather than randomized, placebo-controlled trials. These reports consistently note adverse events such as nausea, flushing, yawning, and swings in blood pressure and heart rate. Long-term, controlled human safety data are essentially absent. As a result, the scientific basis for any claims about effects in humans is weak. This overview does not provide doses, routes of administration, or any instructions for human use; it reports only what is recorded in the published research and clinical literature.
Documented safety concerns: moles and melanoma
The MT-2 literature contains clearly described safety concerns, which we report honestly. Case reports document darkening and enlargement of existing moles, appearance of new and atypical (dysplastic) nevi, and even melanoma in individuals who injected MT-2. Sivyer (2012) described rapid mole changes in a teenager with FAMMM syndrome (familial atypical multiple mole and melanoma) who combined Melanotan with sunbed use. Separately, systemic toxicity with rhabdomyolysis was reported after a large injection (Nelson et al., 2012). Case reports alone cannot establish causation, but they flag serious concerns; moreover, pigmentation changes make dermatological monitoring of moles harder. Because of these documented risks, maximum caution is warranted with MT-2.
Regulatory status
Melanotan-2 is not approved as a medicine anywhere: it holds no marketing authorization from the FDA or EMA and is not intended for human or veterinary use. Regulators in several countries have issued warnings. Slovenia's JAZMP, in its 23 April 2026 warning on injectable peptides, explicitly named Melanotan and listed known potentially serious and long-term consequences such as darkening of existing skin moles, possible vision loss, stroke, and anaphylactic reaction. JAZMP notes that such products are often marketed as 'for research purposes' yet offered in a form implying direct human use, while their quality, safety and efficacy remain unverified. This overview is consistent with that warning: it treats MT-2 strictly as a research substance.
Research use and quality
All products referred to in this overview are strictly for research use only (RUO) and are not intended for human or animal use, diagnosis, or treatment. The purpose of this article is educational: to summarize the mechanisms under study and the regulatory context, not to encourage any use. For serious research, identity and purity of the substance are essential. peptid.si provides laboratory-verified purity for every batch and a publicly accessible certificate of analysis (COA) in the COA Vault, so researchers can confirm what they are actually studying. Responsible practice means following applicable regulations, the warnings of competent authorities (JAZMP), and good laboratory practice.
References / Links
- Tian X, Gu Y, Wang X, et al. (2024). Melanocortin 1 receptor mediates melanin production by interacting with the BBSome in primary cilia. PLoS Biology. PLOS
- Sivyer GW (2012). Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. Dermatology Practical & Conceptual. PubMed
- Nelson ME, Bryant SM, Aks SE (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology. PubMed
- Javna agencija RS za zdravila in medicinske pripomočke (JAZMP) (2026). Opozorilo glede uporabe peptidov za injiciranje. JAZMP. Web
